期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

氟尿嘧啶药理学及其相关代谢酶的遗传药理学进展 被引量：10

下载PDF
导出
摘要 由于受环境污染、饮酒、吸烟等不良生活习惯的影响，恶性肿瘤已成为严重危害人类健康的常见病、多发病［1］。1957年Duschinsky等合成的第一代氟化嘧啶药物-氟尿嘧啶（5-FU）对消化道癌、乳腺癌、肺癌等多种恶性肿瘤均有抑制作用，但缺点是有效剂量与中毒量相近，在杀死癌细胞的同时也使正常细胞严重受损。本文结合文献对氟尿嘧啶及其相关代谢酶的遗传药理学研究进展进行综述，旨在为临床合理用药提供参考依据。
作者 吴丽敏 王鸿梅 李军
机构地区 山东大学药学院 山东省淄博市齐都医院 山东大学附属省立医院
出处 《浙江临床医学》 2014年第3期481-483,共3页 Zhejiang Clinical Medical Journal
关键词 遗传药理学 氟尿嘧啶 代谢酶 不良生活习惯 临床合理用药 恶性肿瘤 环境污染 人类健康
分类号 R968 [医药卫生—药理学]
  • 相关文献

参考文献19

  • 1Dahl O, Fluge O, Carlsen E,et al. Final results of a randomized phase IIIstudy on adjuvant chemotherapy with 5-FU and levamisol in colon and rectum cancer stage II and IIIby the Norwegian Gastrointestinal Cancer Group . Acta Oncol, 2009, 48(3):368~376.
  • 2周志伟,王国强,万德森,潘志忠,李苏,陈功,廖海.二氢嘧啶脱氢酶活性与结直肠癌患者5-FU辅助化疗毒性关系的研究[J].癌症,2004,23(z1):1512-1516. 被引量：6
  • 3Zachariae tk, Paulsen K, Mehlsen M, et al. Chemot herapy-in-duced nausea, vomiting, and fatigue-the role of individual differences related to sensory perception and autonomic reactivity.Psychother Psychosom, 2007,76 (6) :376~384.
  • 4Ciccolini J, Gross E, Dahan L, et al. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? . Clin Colorectal Cancer,2010,9(4):224~228.
  • 5Mounier-Boutoille H, Boisdron-Celle M, Cauchin E, et al. Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and U TG1A1 gene mutation.Br J Clin Pharmacol, 2010,70 (2):280~283.
  • 6Tomiak A, Vincent M, Kocha W, et al. Standard dose (Mayoregimen) 5-fluorouracil and low dose fohnic acid: prohibitive toxicity? . Am J Clin Oncol,2000,23(1) :94~98.
  • 7Townsend DM, Tew KD. The role of glutathione-S-transferase in antrcancer drug resistance. Oncogene, 2003, 22:7369~7375.
  • 8Kitazono M, Takebayashi Y, Ishitsuka K, Takao S,Tani A, Furukawa T, Miyadera K, Yamada Y, Aik-ou T, Akiyama S. Prevention ofhypoxia- inducedapoptosis by the angiogenic factor thymidine phos-phorylase. Biochem Biophys lkes Commun 1998, 253:797-803.
  • 9Matsuura T, Kuratate I, Teramachi K, Osaki M,Fukuda Y, Ito H. Thymidine phosphorylase ex-pression is associated with both increase of intra-tumoral microvessels and decrease of apoptosis inhuman colorectal carcinomas. Cancer Res 1999, 59:5037~5040.
  • 10马韬,叶正宝,纪玉宝,刘炳亚,朱正纲,尹浩然,林言箴.大肠癌TP及DPD表达与临床特征的关系[J].世界华人消化杂志,2006,14(12):1183-1187. 被引量：3

二级参考文献13

  • 1[1]Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil [J]. Clin Cancer Res,1999,5(8): 2006-2011.
  • 2[2]van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD)deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene [J].Clin Cancer Res, 2000, 6(12): 4705 -4712.
  • 3[3]Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU) -related toxicity compared with controls [J]. Clin Cancer Res, 2001, 7(9):2832 - 2839.
  • 4[4]van Kuilenburg AB. Dihydropyrimidine dehydrogenase and efficacy and toxicity of 5-fluorouracil [J]. Eur J Cancer, 2004,40(7): 939 - 950.
  • 5[6]Guimbaud R, Guichard S, Dusseau C, et al. Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumor tissues of colon and liver in humans [J]. Cancer Chemother Pharmacol,2000, 45(6): 477-482.
  • 6[7]Mcleod HL, Sludden J, Murray GI, et al. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors [J]. BrJ Cancer, 1998, 77(3): 461-465.
  • 7[8]Kobayashi K, Sumi S, Kidouchi K, et al. A case of gastric cancer with decreased dehydropyrimindine dehydrogenase activity [J]. Gan To Kagaku Ryoho, 1998, 25(8): 1217 - 1219.
  • 8[9]Gamelin E, Boisdron-Celle M, Guerin-Meyer V, et al.Correlation between Uracil and Dihydrouracil Plasma Ratio,Fluorouracil(5-FU) Pharmacokinetic Parameters, and Tolerance in Patients with Advanced colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage [J]. J Clin Oncol, 1999, 17 (4): 1105-1110.
  • 9[12]Harris BE, Song R, Soong SJ, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion [J].Cancer Res, 1990, 50(1): 197-201.
  • 10[13]Lu Z, Zhang R, Robert RB. Dihydropyrimidine Dehydrogenase Activity in Human Peripheralthe blood Mononuclear Cells and Liver: Population Characteristics, Newly Identified Deficient Patients, and Clinical Implication in 5-Fluorouracil Chemotherapy [J]. Cancer Res, 1993, 53 (22): 5433-5438.

共引文献7

同被引文献87

引证文献10

二级引证文献57

浙江临床医学
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部